In The Medicine Maker, ERS Genomics CEO, Eric Rhodes explores the power and flexibility of CRISPR/Cas9 for the antibody manufacturing pipeline, including for next-generation antibody-drug…
Dublin, Ireland, January 5, 2023: ERS Genomics announced that its first Canadian patent, CA 2872241, with broad claims to compositions and methods of using CRISPR/Cas9…
Dublin, Ireland, December 1, 2022: ERS Genomics Limited (‘ERS’) is pleased to announce a new license agreement with Cosmo Bio. This is a non-exclusive license…
Dublin, Ireland, 17 November 2022: ERS Genomics Limited (‘ERS’) is pleased to announce ATLATL Innovation Centre (‘ATLATL’) as its non-exclusive agent for licensing ERS’ intellectual…
ERS Genomics and Lepton Pharmaceuticals LTD Enter CRISPR/Cas9 License Agreement License allows Lepton, with their proprietary Castling Technology, to develop and commercialize products and services…
Dublin, Ireland, June 28, 2022: ERS Genomics Limited (‘ERS’) is pleased to announce a new license agreement with Cytosurge AG (“Cytosurge”). This is a…